HESTERBIO · NSE
Hester Biosciences Limited
₹2,195.6
-2.24% (-₹50.2)
Prev. close
₹2,245.8
Volume
5,041
Delivery %
73.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms. It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajiv Dinesh Gandhi B.Com
Headquarters
Mehsana
Employees
483
Website
hester.inExchange
View on NSE ↗Key stats
Market cap
₹1,867.77 Cr
P/E ratio (TTM)
13.8
Dividend yield
0.49%
EPS (TTM)
₹158.78
Beta (1Y · daily vs NIFTY 50)
0.82
Beta (5Y · monthly vs NIFTY 50)
1.43
Shares float
26.55 L
EPS · quarter ended Jun 2026
₹113.71
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹214.33 Cr | ₹235.01 Cr | ₹266.09 Cr | ₹304.55 Cr | ₹311.10 Cr | ₹332.60 Cr | |
| EBITDA | ₹73.34 Cr | ₹73.72 Cr | ₹66.00 Cr | ₹58.25 Cr | ₹64.71 Cr | ₹102.13 Cr |
| ₹34.70 Cr | ₹39.48 Cr | ₹26.63 Cr | ₹18.89 Cr | ₹27.49 Cr | ₹55.64 Cr | |
| Diluted EPS | ₹40.79 | ₹46.41 | ₹31.3 | ₹22.2 | ₹32.31 | ₹65.4 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹411.05 Cr | ₹562.16 Cr | ₹669.97 Cr | ₹662.35 Cr | ₹653.39 Cr | ₹677.94 Cr | |
| — | ₹228.17 Cr | ₹274.15 Cr | ₹244.38 Cr | ₹213.25 Cr | ₹194.79 Cr | |
| Stockholders' equity | ₹228.31 Cr | ₹259.99 Cr | ₹279.73 Cr | ₹291.79 Cr | ₹314.26 Cr | ₹360.24 Cr |
Fixed assets, CWIP, Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹58.04 Cr | ₹8.81 Cr | ₹23.60 Cr | ₹48.18 Cr | ₹64.51 Cr | ₹64.14 Cr | |
| Investing cash flow | ₹-38.36 Cr | ₹-116.59 Cr | ₹-77.00 Cr | ₹-22.61 Cr | ₹-19.00 Cr | ₹-2.87 Cr |
| ₹-18.22 Cr | ₹111.61 Cr | ₹41.76 Cr | ₹-26.09 Cr | ₹-51.72 Cr | ₹-48.79 Cr | |
| Capital expenditure | ₹-40.74 Cr | ₹-95.71 Cr | ₹-77.76 Cr | ₹-24.40 Cr | ₹-20.59 Cr | ₹-17.83 Cr |
| End cash position | ₹21.27 Cr | ₹24.75 Cr | ₹13.16 Cr | ₹12.31 Cr | ₹5.59 Cr | ₹2.77 Cr |
Depreciation & amortization, Change in working capital, Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 53.73% |
| Public | 46.27% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Hester Biosciences Limited | ₹2,013.92 Cr | ₹2,245.8 | 13.9 | 5.59 | 15.4% | 0.54 | +6.9% | +9.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.